Physician profile
Ryan Wang
NPI 1518545771
$1,213.74
in general payments reported to CMS, 2019-2025
16 companies · $1,038 in 2025
The $1,038 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $176 · 2025: $1,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $348.73 | 2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $153.03 | 2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $146.66 | 2025 | Repatha, Otezla, Krystexxa |
| Glaxosmithkline, LLC. | $129.34 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $112.15 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $62.94 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.39 | 2025 | |
| Esperion Therapeutics, INC. | $35.68 | 2025 | Nexletol |
| Sumitomo Pharma America, INC. | $29.51 | 2025 | Gemtesa |
| Astellas Pharma US INC | $24.17 | 2025 | Veozah |
| Kowa Pharmaceuticals America, INC. | $24.12 | 2024 | Zoryve |
| Merck Sharp & Dohme LLC | $24.03 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Sanofi Pasteur INC. | $23.57 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.08 | 2025 | Jardiance |
| Novo Nordisk INC | $18.53 | 2024 | Ozempic, Rybelsus |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $13.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.